Biallelic *RFX6* mutations can cause childhood as well as neonatal onset diabetes mellitus

This paper has been corrected since online publication and a erratum also appears in this issue

Francis H Sansbury¹,³,⁴, Birgül Kirel²,⁴, Richard Caswell¹, Hana Lango Allen¹, Sarah E Flanagan¹, Andrew T Hattersley¹, Sian Ellard*¹ and Charles J Shaw-Smith¹

Neonatal diabetes is a highly genetically heterogeneous disorder. There are over 20 distinct syndromic and non-syndromic forms, including dominant, recessive and X-linked patterns of inheritance well described, comprising to date over 20 distinct syndromic and non-syndromic forms with a combined incidence of around 1 in 100,000 births.¹

During early childhood, type 1 diabetes predominates. However, monogenic causes of diabetes should also be considered in this group. Examples of syndromic monogenic diabetes in this age range include Wolfram syndrome,² thiamine-responsive megaloblastic anemia syndrome³ and diabetes due to heterozygous mutations in the transcription factor GATA6, a cause of neonatal diabetes in association with congenital heart disease and other malformations.⁴

Biallelic mutations in *RFX6* (regulatory factor X, 6) cause neonatal diabetes mellitus in association with intestinal atresias, and hepatobiliary abnormalities. This condition has been designated as Mitchell–Riley syndrome.⁵ To date there have been eight genetically confirmed cases, comprising seven probands and one sibling.⁶⁻¹⁰ Typically, fetal abnormality is suspected pre-natally and a diagnosis of duodenal and/or jejunal atresia confirmed shortly after birth. Low birth weight and ongoing feeding difficulties relating to bowel surgery contribute to failure to thrive. Cholestasis, partly secondary to total parenental nutrition and partly due to a poorly defined primary intrahepatic cholangiopathy may result in hepatic failure. Diabetes is diagnosed within the first few weeks of life. Prognosis is poor, with death occurring within the first 6 months in five of the cases described to date.

Here, we report the first cases of Mitchell–Riley syndrome in which the onset of diabetes occurred outside the neonatal period. We compare their clinical and molecular characteristics with the eight previously reported cases.

**METHODS**

**Genetic testing**

Genomic DNA was extracted by standard protocols and the proband was tested for mutations in all known neonatal diabetes genes using a previously described targeted next generation sequencing assay.¹¹ Targeted sequence capture utilized a custom cRNA bait library (Agilent, Santa Clara, CA, USA) to enrich for exons and flanking sequences from 29 genes, including *RFX6*, in which mutations are known to cause monogenic forms of diabetes.¹¹ Potential mutations were confirmed using Sanger sequencing.

**Literature review**

Cases of Mitchell–Riley syndrome were identified from PubMed (http://www.ncbi.nlm.nih.gov/pubmed). Those cases in whom confirmatory biallelic mutations in *RFX6* had been identified were included in our review.

**CLINICAL REPORTS AND RESULTS**

Case 1 (Figure 1, I5), current age 9 years, is a female born at 32 weeks gestation, birth weight 1.65 kg (42nd centile), with duodenal atresia, jejunal web and Meckel’s diverticulum. She underwent operative intervention for these malformations before being discharged from hospital at 3 months of age. During an admission at the age of 2 years, hyperglycemia (10.6 mmol/l, random sample) had been noted. However, no further investigation or treatment was put in place at that

1Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK; 2Endocrinology Unit, Faculty of Medicine, Department of Pediatrics, Eskişehir Osmangazi University, Eskişehir, Turkey; 3Current address: St Michael’s Hospital, University Hospitals Bristol NHS Foundation Trust, Southwell Street, Bristol, UK;
4These authors contributed equally to this work.
5Correspondence: Professor S Ellard, Royal Devon and Exeter NHS Trust, Institute of Biomedical Science, Barrack Road, Exeter EX2 5DW, UK. Tel: +01392 411611; E-mail: sian.ellard@nhs.net

Received 24 October 2014; revised 3 March 2015; accepted 24 April 2015; published online 12 August 2015
time. She presented at the age of 3 years with diabetic ketoacidosis. Physical examination revealed no abnormalities other than those associated with elevation of blood glucose at 33.0 mmol/l. Her body weight was 18.5 kg (10–25th centile). Height was 118 cm (25th centile). Investigations showed insulin <2 µ U/ml, C-peptide 0.023 ng/ml, blood pH: 7.40; urine ketone: +++, HbA1c 8.96%, and C-peptide 0.39 ng/ml, blood: pH: 7.41; urine ketones: negative; and age at diagnosis was determined 1 year previously in another hospital; no treatment was initiated at that time. Physical examination was remarkable. His body weight was 17.5 kg (10th centile). Height was 113 cm (25th centile). Investigations at this time showed: blood glucose 16.0 mmol/l; insulin: <2 µ U/ml; C-peptide 0.39 ng/ml, blood: pH: 7.41; urine ketones: negative; and HbA1C: 7.96%. Anti-GAD, IAA and ICA antibodies negative. His current insulin requirement is ~ 0.7 units/kg per day of long-acting insulin with occasional bolus insulin.

Otherwise, her past medical history was notable for multiple hospital admissions due to gastrointestinal bleeding. At the age of 3 years, she underwent a small intestinal resection, histological examination of which revealed the presence of patches of gastric heterotopia within the small bowel. The gastro-intestinal bleeding subsequently resolved. Additional investigation revealed absent gall bladder with otherwise normal biliary tract. Liver function tests have always been within normal limits.

She has a healthy 16-year-old sister. A brother died of prematurity and meconium aspiration at 1 week of age. An identical twin was diagnosed with duodenal atresia and underwent corrective surgery at 2 days of age. She died of complications of prematurity and surgery at the age of 1 month.

Case 2 (Figure 1, I12), her double first cousin, current age 9 years, is a male infant who was born at 34 weeks gestation, birth weight 1.70 kg (7th centile), with duodenal atresia and mid-gut malrotation. He was diagnosed with diabetes having presented with hyperglycemia (16.0 mmol/l) at the age of 6 years. He had no prior symptoms suggestive of diabetes and hyperglycemia had been identified at home by his mother. He did have a history of asymptomatic fasting hyperglycemia (7.2 mmol/l) determined 1 year previously in another hospital; no treatment was initiated at that time.

Physical examination was remarkable. His body weight was 17.5 kg (10th centile). Height was 113 cm (25th centile). Investigations at this time showed: blood glucose 16.0 mmol/l; insulin: <2 µ U/ml; C-peptide 0.39 ng/ml, blood: pH: 7.41; urine ketones: negative; and HbA1C: 7.96%. Anti-GAD, IAA and ICA antibodies negative. His current insulin requirement is ~ 0.7 units/kg per day of long-acting insulin before meals and 4 units insulin glargine before bed. His last recorded HbA1c level was 7.2%.

His past history is notable for chronic iron deficiency anemia. Despite extensive investigation at two different hospitals, it has not been possible to identify a cause for this. No structural abnormality of the hepatobiliary tract has been identified, and his liver function tests have always been within normal limits.

He has healthy sisters, current ages 20 and 11 years. Another sister died of complications of cerebral palsy at the age of 17 years. A brother died of complications of prematurity at 1 week of age. His mother was diagnosed with diabetes 4 years previously. There was no history of parental consanguinity. However, the mothers of the two cases are sisters and the fathers are brothers, making the affected individuals double first cousins.

Genetic testing showed that both children are compound heterozygotes for the RFX6 nonsense mutations c.2176C>T (p.Arg726X) and c.2596C>T (p.Arg866X) in exons 17 and 18, respectively (Figure 2). The fathers were heterozygous for p.Arg726X and the mothers heterozygous for p.Arg866X. Further testing demonstrated that the mutations had been inherited from both grandmothers.
Other family members had been diagnosed with diabetes in adulthood, as shown in the pedigree and in Table 1. The mother of case 2, both grandmothers and the surviving (maternal) grandfather (Figure 1, I16, III2, III4 and III3, respectively) developed adult-onset diabetes. Age of diagnosis for these four individuals is provided in Figure 1. All four are non-obese (BMI data not available) and treated with an oral hypoglycaemic agent. C-peptide and HbA1c levels were assayed in all four heterozygote parents and in both heterozygote grandmothers, and, for comparison, in one further non-diabetic heterozygote and a further eight non-diabetic family members without a mutation (see Figure 1). For heterozygotes in the family, there was no significant difference in C-peptide levels between those who had and had not developed diabetes. There was also no difference in HbA1c between the non-diabetic heterozygotes and those who are negative for the relevant familial mutation. Taking these data together, there is no support for the idea that being heterozygous for either RFX6 mutation is a risk factor for abnormal HbA1c or C-peptide levels, or diabetes.

It remains possible that heterozygous carriers of RFX6 5’ mutations may have increased risk of early-onset type 2 diabetes. This could be evaluated in a larger cohort by testing of beta cell function as a function of age in these subjects in comparison with controls.

A review of the clinical phenotype observed in previously published cases is shown in Table 1. All cases with a molecularly confirmed diagnosis of Mitchell–Riley syndrome are included, together with the present cases. The eight previously published cases demonstrate a high degree of phenotypic concordance. Duodenal atresia is a present in all cases, with or without jejunal atresia/mid-gut malrotation. Gall-bladder agenesis is present in 7/8. All cases had evidence of liver involvement with intrahepatic cholestasis in 7/8 cases and ascites in a further case. Five of the eight children had died, all within the first year of life. Aside from the difference in age of onset of diabetes in the two new cases, the phenotype differed from previously published cases in the absence of any liver pathology, although one of the cases (case 1) had absent gall bladder. This relatively milder phenotype is reflected in the greater age of survival of the two cases in the present report.

**DISCUSSION**

We report double first cousins in whom the identification of biallelic RFX6 mutations has confirmed a diagnosis of Mitchell–Riley syndrome. These new cases are the first with Mitchell–Riley syndrome in whom the diagnosis of diabetes was not made in the neonatal period, all other cases to date having been diagnosed within the first 2 weeks of life. The diagnosis of diabetes in these cousins at the ages of 3 and 6 years is therefore significantly different from the previously expected phenotype. In both of the cousins, a period of asymptomatic hyperglycemia of at least 1 year preceded a formal diagnosis of diabetes.

The results of mutation analysis of the eight molecularly confirmed probands (excluding those in the present report) suggest a possible genotype/phenotype correlation. Among the nine mutations identified in these eight cases (one a compound heterozygote, the remaining seven homozygous), six affect splicing and/or the reading frame in exons 2–8; the remaining three are mis-sense mutations clustering within or close to the DNA-binding domain (Figure 2). The cases in the present report are compound heterozygotes for premature truncating mutations in exons 17 and 18 of the 19 exon RFX6 gene, the first such mutations in RFX6 to be described. The exon 18 mutation, c.2596C>T (R866X) is predicted to escape nonsense-mediated decay because it lies within 50 nucleotides of the last exon–exon boundary of the gene. A partially truncated version of the wild-type protein, which comprises 928 amino acids, is therefore predicted to be produced, possibly with some function given the full preservation of the DNA-binding domain. The second mutation, c.2176C>T (R726X), is predicted to subject to nonsense-mediated decay.

There are reports in the literature of distinct phenotypes associated with mutated transcripts depending upon the presence or absence of nonsense-mediated decay. 3’ mutations in SOX10 result in a severe neurocristopathy designated PCWH.1,2 More 5’ mutations result in the more restricted phenotype of Waardenburg–Shah syndrome. Transcripts with 3’ mutations escape nonsense-mediated decay and in this instance the phenotype is postulated to be more severe than that due to more 5’ mutations because failure of the NMD pathway results in production of a protein with a dominant negative effect. A distinct clinical phenotype is also postulated in instances of 3’ mutations in the FBN1 gene, with the same proposed mechanism of escape from NMD.1,3

In the present case of biallelic mutations in RFX6, the transcript with the 3’-most RFX6 mutation (c.2596C>T) is predicted to escape NMD, a possibility which could be tested by analyzing levels of wild-type and mutated transcripts in a suitable experimental assay. It is possible that escape from NMD could lead to some retention of function of the RFX6 protein generated from that allele, with a
Table 1: Details of individuals with biallelic mutations in RFX6

| Case no. | Relationship to Proband no. in Smith (ref. 5) | Sex | Ethnic origin | Birth weight | Gestational age at birth | GI atresia/malrotation | Hepatobiliary | Pancreas | Other | Outcome | RFX6 mutation-nucleotide | RFX6 mutation-protein | Reference |
|----------|-----------------------------------------------|-----|---------------|--------------|--------------------------|------------------------|---------------|----------|-------|---------|--------------------------|------------------------|-----------|
| 1        | n/a                                           | M   | Pakistani     | 1540 g       | 36 weeks                 | Day 1                  | DA, JA        | GBA      | AP    | Malabsorption unresponsive to pancreatic supplements/bile acids; cholestasis | c.380+2T>C homozygous | p.?       | Mitchell et al.6        |
| 2        | Sibling of case 1                             | F   | Pakistani     | 1310 g       | 34 weeks                 | Day 2                  | DA, JA        | GBA      | AP    | Intrahepatic cholestasis; partial villous atrophy | c.380+2T>C homozygous | p.?       | Mitchell et al.6        |
| 3        | n/a                                           | F   | Not stated    | 2295 g       | 39 weeks                 | Day 2                  | Duodenal web and malrotation | GBA      | Small Pancreas | Intrahepatic cholestasis; bilobar inguinal hernias | c.672+2T>G homozygous | p.7/p.? | Chappell et al.1         |
| 4        | n/a                                           | F   | Pakistani     | 1700 g       | 35 weeks                 | Day 8                  | DA, malrotation | GBA     | Intrahepatic cholestasis; anteriorly placed anus | c.542G>A homozygous | p.Arg181Gly | Martinovici et al.9     |
| 5        | n/a                                           | M   | Not stated    | 1340 g       | Soon after birth         | DA, JA (apple peel-type), intestinal malrotation | DA      | GBA      | Pancreatic hypoplasia | c.776_780+8del13 homozygous | p.?       | Smith et al.5           |
| 6        | n/a                                           | M   | French, non-consanguineous | 10th centile | 35 weeks                 | Day 2                  | No abnormality reported | No abnormality reported | Ascites, sepsis, gastro-intestinal haemorrhage | c.776_780+8del13 homozygous | p.?       | Smith et al.5           |
| 7        | n/a                                           | M   | Arab-Israeli  | 1490 g       | 38 weeks                 | Day 1                  | DA, JA, intestinal malrotation | GBA      | AP    | Intrahepatic cholestasis; red cell aplasia confirmed on bone marrow biopsy | c.781>2_787delAGGTT-GATAinsG homozygous | p.?       | Spiegel et al.9          |
| 8        | n/a                                           | M   | Vietnamese    | 1375 g       | 34 weeks                 | Day 1                  | DA, intestinal malrotation | GBA      | AP    | Intrahepatic cholestasis; malabsorption unresponsive to pancreatic supplements/bile acids | c.779A>C homozygous | p.Lys260Thr | Concepcion et al.10     |
| 9        | n/a                                           | F   | Turkish       | 1650 g       | 32 weeks                 | 3 years                | DA, jejunal web, Meckel's diverticulum | GBA     | No abnormality reported | No abnormality reported | c.2176C>T homozygous | p.Arg726X | Present report          |
| 10       | Double-first cousin of case 9                 | M   | Turkish       | 1700 g       | 34 weeks                 | 6 years                | DA, mid-gut malrotation | GBA     | No abnormality reported | No abnormality reported | c.2176C>T homozygous | p.Arg726X | Present report          |

Abbreviations: GBA, gall bladder agenesis; DA, duodenal atresia; JA, jejunal atresia; AP, annular pancreas.

European Journal of Human Genetics
resulting milder phenotype with respect to age of onset of diabetes and other clinical features.\textsuperscript{14}

The data presented support the idea that biallelic mutations in \textit{RFX6} should be considered in any infant presenting with duodenal or jejunal atresia with or without intestinal malrotation, especially in the context of possible autosomal recessive inheritance. A genetic diagnosis confers not only the advantage of establishing a molecular genetic diagnosis, but also alerts the clinician to the future possibilities of onset of diabetes during infancy or childhood, as well as possible hepatobiliary complications.

In summary, we report two individuals each with compound heterozygous \textit{RFX6} nonsense mutations and an intestinal phenotype consistent with Mitchell–Riley syndrome, but with onset of diabetes in childhood rather than in the first 2 weeks of life. Genetic testing for \textit{RFX6} mutations should be considered in patients presenting with intestinal atresias in the absence of neonatal diabetes, especially where sibling recurrence or parental consanguinity point to possible autosomal recessive inheritance.

\textbf{CONFLICT OF INTEREST}

The authors declare no conflict of interest.

\textbf{ACKNOWLEDGEMENTS}

The authors would like to thank the family for their help and cooperation in the preparation of this manuscript. FHS was funded by an NIHR academic clinical fellowship. SE and ATH are employed as core members of staff within the National Institute for Health Research–funded Exeter Clinical Research Facility. SE and ATH are Wellcome Trust Senior Investigators and ATH is an NIHR Senior Investigator.

\textsuperscript{1} Iafusco D, Massa O, Pasquino B et al: Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. \textit{Acta Diabetol} 2012; 49: 405–408.
\textsuperscript{2} Barrett TG, Bundey SE: Wolfram (DIDMOAD) syndrome. \textit{J Med Genet} 1997; 34: 838–841.
\textsuperscript{3} Shaw-Smith C, Flanagan SE, Patch AM et al: Recessive \textit{SLC19A2} mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia. \textit{Pediatr Diabetes} 2012; 13: 314–321.
\textsuperscript{4} Lango Allen H, Flanagan SE, Shaw-Smith C et al: GATA6 haploinsufficiency causes pancreatic agenesis in humans. \textit{Nat Genet} 2011; 44: 20–22.
\textsuperscript{5} Smith SB, Qu H, Tuley N et al: \textit{Rfx6} directs islet formation and insulin production in mice and humans. \textit{Nature} 2010; 463: 776.
\textsuperscript{6} Mitchell J, Purkhtakee Z, Lo B et al: Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gall bladder hypoplasia: search for the aetiology of a new autosomal recessive syndrome. \textit{Diabetologia} 2004; 47: 2160.
\textsuperscript{7} Chappell L, Gorman S, Campbell C et al: A Further Example of a Distinctive Autosomal Recessive Syndrome Comprising Neonatal Diabetes Mellitus, Intestinal Atresias and Gall Bladder Agenesis. \textit{Am J Med Genet} 2008; 146A: 1713.
\textsuperscript{8} Martinovic D, Ranzy V, Vanden et al: Neonatal hemochromatosis and Martinez-Frias syndrome of intestinal atresia and diabetes mellitus in a consanguineous newborn. \textit{Eur J Med Genet} 2010; 53: 25.
\textsuperscript{9} Spiegel R, Dobbie A, Hartman C et al: Clinical characterization of a newly described neonatal diabetes syndrome caused by \textit{RFX6} mutations. \textit{Am J Med Genet} 2011; 155A: 2821.
\textsuperscript{10} Concepcion JP, Reh CS, Daniels M et al: Neonatal diabetes, gallbladder agenesis, duodenal atresia, and intestinal malrotation caused by a novel homozygous mutation in \textit{RFX6}. \textit{Pediatr Diabetes}. 2014; 15: 67–72.
\textsuperscript{11} Ellard S, Lango Allen H, De Franco E et al: Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. \textit{Diabetologia} 2013; 56: 1958–1963.
\textsuperscript{12} Inoue K, Khajavi M, Ohyama T et al: Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. \textit{Nat Genet} 2004; 36: 361–369.
\textsuperscript{13} Horn D, Robinson PN: Progeroid facial features and lipodystrophy associated with a novel splice site mutation in the final intron of the FBN1 gene. \textit{Am J Med Genet A} 2011; 155A: 721–724.
\textsuperscript{14} De Franco E, Shaw-Smith C, Flanagan SE et al: GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency. \textit{Diabetes} 2013; 62: 993–997.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/